BofA/Merrill Lynch Upgrades AstraZeneca (AZN) to Neutral
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Price: $92.77 --0%
Rating Summary:
19 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
19 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BofA/Merrill Lynch upgraded AstraZeneca (NYSE: AZN) from Underperform to Neutral.
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $43.90 yesterday.
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $43.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Ca
- Applied Materials (AMAT) PT Lowered to $650 at BofA Securities, 'our top semicap pick is LRCX'
- Citi Upgrades Shenzhen T&S Communication (300570:CH) to Neutral
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
